Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taptiqom vs Taflotan in open-angle glaucoma or ocular hypertension (China phase 3)
CTR20182196Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tafluprost + timolol in open-angle glaucoma (OAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Nov 2018; status: completed.
02
Drugs
tafluprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on CTR20182196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182196.